PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Positive gross profit growth while TRVN is negative. John Neff would see a clear operational edge over the competitor.
8.25%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
8.25%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
12.55%
Net income growth above 1.5x TRVN's 1.02%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.52%
EPS growth at 75-90% of TRVN's 17.92%. Bill Ackman would push for improved profitability or share repurchases to catch up.
15.52%
Diluted EPS growth at 75-90% of TRVN's 17.92%. Bill Ackman would expect further improvements in net income or share count reduction.
3.21%
Share reduction more than 1.5x TRVN's 20.59%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.21%
Diluted share reduction more than 1.5x TRVN's 20.59%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.46%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
18.52%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
Positive long-term OCF/share growth while TRVN is negative. John Neff would see a structural advantage in sustained cash generation.
77.11%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
-27.06%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
72.83%
Net income/share CAGR above 1.5x TRVN's 11.02% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
70.62%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
-36.68%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.68%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-48.78%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-45.28%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while TRVN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Negative asset growth while TRVN invests at 16.15%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while TRVN stands at 75.90%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
R&D growth drastically higher vs. TRVN's 6.74%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-40.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.